Android app Apple app link

J&J Digs Deep In Neuropsych With A $14.6 Billion Acquisition

By Investor's Business Daily   |   1 week ago
J&J Digs Deep In Neuropsych With A $14.6 Billion Acquisition

Intra-Cellular's shares surged as news suggests J&J may acquire the neuropsych-focused biotech company at a premium of 39%. Intra-Cellular's Caplyta drug for schizophrenia and bipolar disorders, along with potential in depression treatment, boosts its value in the deal.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.